Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Gene Therapy

Volume 10 Issue 5
ISSN: 1566-5232
eISSN: 1875-5631


   All Titles

  Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
  pp.341-349 (9) Authors: J. Fraser Wright, Jennifer Wellman, Katherine A. High

Recombinant adeno-associated virus (AAV) -based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A recent milestone has been the safety and efficacy observed using recombinant AAV2 expressing retinal pigment epithelial associated 65KDa protein for Leber Congenital Amaurosis. This review summarizes manufacturing and characterization of ‘AAV2-hRPE65v2’, the vector used in one completed Phase I/II clinical trial. Regulatory challenges and strategies that were successfully used for this groundbreaking trial are described.

  Keywords: AAV vectors, regulatory affairs, cGMP, Leber Congenital Amaurosis, AAV2-hRPE65v2, LCA, Adeno associated virus, RPE65, gene therapy, electroretinograms, alpha1-antitryspin deficiency, Alzheimer's disease, arthritis, Batten's disease, Canavan's disease, cystic fibrosis, Hemophilia B, HIV infection, Parkinson's disease, muscular dystrophy, prostate cancer, malignant melanoma, HEPA, cation exchange column chromatography, HEK293, CRUDE CELL HARVEST, ampicillin, reverse transcriptase Q-PCR, Column chromatography
  Affiliation: Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2014   Bentham Science Publishers